Citations 21
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Luskin, Marlise R. , Lee, Ju-Whei, Fernández, Hugo F. , Bennett, John M. , Ketterling, Rhett P. , Levine, Ross L. , Litzow, Mark R. , Paietta, Elisabeth , Patel, Jay P., Racevskis, Janis, Rowe, Jacob M. , Tallman, Martin S. , Sun, Zhuoxin , Luger, Selina M. , Luskin, Marlise R , Lee, Ju‐Whei , Abdel‐Wahab, Omar , Lazarus, Hillard M. , Ketterling, Rhett P
Blood | January 11, 2016 | Volume: 127 | Issue: 12 | Pages: 1551-1558
Key Points High-dose daunorubicin benefits AML patients with favorable and intermediate cytogenetics and with FLT3-ITD, NPM1, and DNMT3A mutations. High-dose daunorubicin is required for the favorable impact of the NPM1 mutation in AML.